Efficacy of sodium glucose cotransporter 2 inhibitors as an adjunct treatment for patients with diabetes type 2.
CONCLUSION: The use of SGLT2 inhibitors in insulin treated T2D patients resulted in reduction of HbA1c, which was associated to weight loss, cHDL increase and SBP decrease.
PMID: 30503071 [PubMed - as supplied by publisher]
Source: Medicina Clinica - Category: General Medicine Tags: Med Clin (Barc) Source Type: research
More News: Cholesterol | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | General Medicine | Insulin | Men | SGLT2 Inhibitors | Sodium | Weight Loss